Penrhos Bio is currently undertaking a Series A investment raise. This investment will accelerate our regulatory roadmap for the Remora™ technology and unlocks a number of higher value markets such as marine fouling and human healthcare. It also empowers our commercial partners to fully leverage the value of the technology in their products, opening new opportunities and segments.
We will be closing this round in the first half of 2023. If you interested in joining us as an investment partner, please contact our Chief Commercial Officer, Dr Steve Howell; cco@remora.bio
